Key Insights

Highlights

Success Rate

77% trial completion

Published Results

11 trials with published results (7%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

9.4%

14 terminated out of 149 trials

Success Rate

77.4%

-9.1% vs benchmark

Late-Stage Pipeline

8%

12 trials in Phase 3/4

Results Transparency

23%

11 of 48 completed with results

Key Signals

11 with results77% success14 terminated

Data Visualizations

Phase Distribution

111Total
Not Applicable (31)
Early P 1 (3)
P 1 (23)
P 2 (42)
P 3 (9)
P 4 (3)

Trial Status

Completed48
Unknown43
Recruiting27
Terminated14
Not Yet Recruiting10
Withdrawn4

Trial Success Rate

77.4%

Benchmark: 86.5%

Based on 48 completed trials

Clinical Trials (149)

Showing 20 of 20 trials
NCT06863272Phase 1Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT07562581Phase 2Not Yet Recruiting

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

NCT04261777Phase 3Terminated

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

NCT07537959Not ApplicableNot Yet Recruiting

Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

NCT06362369Phase 1Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT05095207Phase 1Recruiting

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT06282185Not ApplicableWithdrawn

SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy

NCT06787014Recruiting

Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study

NCT07477457Phase 2Recruiting

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

NCT01613482Phase 3Terminated

TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

NCT05789589Phase 1Recruiting

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

NCT07400809Recruiting

Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.

NCT06700057Recruiting

Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.

NCT05542407Phase 1Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

NCT04009681Phase 1TerminatedPrimary

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT05338658Phase 1RecruitingPrimary

Study of PAT in Patients With Solid Tumor Cancers

NCT06712745Early Phase 1Recruiting

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

NCT03652493Phase 2Completed

Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

NCT06358001Completed

EchoTip AcuCore Post-Market Clinical Study

NCT07154563Recruiting

Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer

Scroll to load more

Research Network

Activity Timeline